详细说明
- Purity>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
- Endotoxin Level<0.10 EU per 1 μg of the protein by the LAL method.
- ActivityMeasured by its binding ability in a functional ELISA. When Recombinant Human LILRB1/CD85j/ILT2 is coated at 2 µg/mL, Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (Catalog # ) binds with a typical ED 50 of 75-450 ng/mL.
- SourceHuman embryonic kidney cell, HEK293-derived
Human LILRB1
(Gly24-His458)
Accession # Q8NHL6HHHHHH N-terminus C-terminus - Accession #
- N-terminal Sequence
AnalysisGly24 - Structure / FormMonomer
- Predicted Molecular Mass48 kDa
- SDS-PAGE65-82 kDa, reducing conditions
| 8989-T2 | | |
| Formulation Lyophilized from a 0.2 μm filtered solution in PBS. | ||
| Reconstitution Reconstitute at 100 μg/mL in PBS. | ||
| Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. | ||
| Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: LILRB1/CD85j/ILT2
LILRB1, also known as CD85j and ILT2, is a 110 kDa transmembrane glycoprotein in the LILR immunoregulatory protein family (1). Mature human LILRB1 consists of a 438 amino acid (aa) extracellular domain (ECD) with 4 tandem Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 4 inhibitory ITIM motifs (2). Alternative splicing generates an additional isoform that lacks the transmembrane and cytoplasmic regions (3). LILRB1 is expressed on the surface of B cells and monocytes, as well as subsets of NK cells, memory/effector CD8 + T cells, gamma δ T cells, and monocyte-derived dendritic cells (3-7). LILRB1 binds to MHC-I as well as non-classical MHC-I molecules ( e.g. HLA-F, HLA-G, and HLA-B27) and the MHC-I mimetic UL18 encoded by cytomegalovirus (3, 5, 8-10). R&D Systems
in-house testing indicates that LILRB1 also binds to Angiopoietin-like 7. Ligation of LILRB1 inhibits the antigen induced proliferation and activation of CD8 + T cells, CD4 + T cells, NK cells, and gamma δ T cells (3, 4, 11-13). On dendritic cells, ligation inhibits the production of IL-10, IL-12p70, and TGF-beta and protects from Fas-mediated apoptosis (7).
in-house testing indicates that LILRB1 also binds to Angiopoietin-like 7. Ligation of LILRB1 inhibits the antigen induced proliferation and activation of CD8 + T cells, CD4 + T cells, NK cells, and gamma δ T cells (3, 4, 11-13). On dendritic cells, ligation inhibits the production of IL-10, IL-12p70, and TGF-beta and protects from Fas-mediated apoptosis (7).
- References:
- Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
- Samaridis, J. and M. Colonna (1997) Eur. J. Immunol. 27:660.
- Colonna, M. et al. (1997) J. Exp. Med. 186:1809.
- Harly, C. et al. (2011) Blood 117:2864.
- Cosman, D. et al. (1997) Immunity 7:273.
- Young, N.T. et al. (2001) J. Immunol. 166:3933.
- Young, N.T. et al. (2008) Blood 111:3090.
- Lepin, E.J.M. et al. (2000) Eur. J. Immunol. 30:3552.
- Shiroishi, M. et al. (2003) Proc. Natl. Acad. Sci. USA 100:8856.
- Allen, R.L. et al. (2001) J. Immunol. 167:5543.
- Ince, M.N. et al. (2004) Immunology 112:531.
- Saverino, D. et al. (2000) J. Immunol. 165:3742.
- Saverino, D. et al. (2002) J. Immunol. 168:207.
- Long Name:Leukocyte Immunoglobulin-like Receptor, Subfamily A (with TM domain), Member 1
- Entrez Gene IDs:10859 (Human)
- Alternate Names:CD85 antigen-like family member J; CD85j antigen; CD85j; Ig-like transcript 2; ILT2; ILT-2; ILT2FLJ37515; Immunoglobulin-like transcript 2; leukocyte Ig-like receptor-1; Leukocyte immunoglobulin-like receptor 1; leukocyte immunoglobulin-like receptor subfamily B member 1 soluble isoform; leukocyte immunoglobulin-like receptor subfamily B member 1; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains); LILRB1; LIR1; LIR1LIR-1MIR-7CD85MIR7CD85 antigen; member 1; MIR7; Monocyte/macrophage immunoglobulin-like receptor 7
400-6226-992